NASDAQ · KNSA
Kiniksa Pharmaceuticals International, plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for KNSA has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.25 | $0.32 | $0.17 | 3 |
| Mar 2027 | $0.25 | $0.27 | $0.22 | 2 |
| Jun 2027 | $0.33 | $0.38 | $0.28 | 2 |
| Sep 2027 | $0.42 | $0.52 | $0.32 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Fintel- RTTNews · 4 h agoShow Me The Money: The $100 Club Beckons For Kiniksa Pharma(RTTNews) – Kiniksa Pharmaceuticals International plc (KNSA) has turned lead drug ARCALYST's strong sales growth into a compelling stock story, with shares delivering more than a 120% gain year-to-date as the drug moves closer to blockbuster status.
- RTTNews · Oct 27, 3:28 PM EDTBiotech Stocks Move Higher: ZURA Surges 21%, PLUR Gains 13%, WVE Rises 7%, KNSA Advances(RTTNews) – Shares of several biotech companies moved higher following quarterly financial results, clinical pipeline updates and strategic developments. Kiniksa Pharmaceuticals raised its 2026 ARCALYST revenue outlook, Pluri announced a U.S. commercialization partnership with ZE
- The Motley Fool · Oct 27, 2:11 PM EDTKiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsKiniksa raised 2026 revenue guidance to over $1.045 billion.
- The Motley Fool · Oct 27, 12:43 PM EDTKiniksa (KNSA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 27, 12:04 PM EDTWhat Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings CallKiniksa Pharmaceuticals Still Has Room to Run After 100% RallyKiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the
- Fintel · Oct 27, 10:54 AM EDTKiniksa Pharmaceuticals, Ltd. Reports Q3 2026 Net Product Revenue of $286.0 millionKiniksa Pharmaceuticals, Ltd. reported its financial results for the third quarter ended September 30, 2026, featuring total revenue of $286.0 million, compared to $180.9 million for the third quarter of 2025. Net product revenue for ARCALYST was $286.0 million, representing appr
- RTTNews · Oct 27, 9:43 AM EDTKiniksa Q3 Revenue Jumps 58%, Raises ARCALYST 2026 Sales Outlook; StocK Up(RTTNews) – Kiniksa Pharmaceuticals International plc (KNSA) reported third quarter 2026 financial results, with revenue growth driven by strong demand for ARCALYST (rilonacept), its treatment for recurrent pericarditis.
- Zacks · Oct 27, 7:50 AM EDTKiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass EstimatesKiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 22, 8:43 PM EDTKiniksa Pharmaceuticals, Ltd. Appoints Ross Moat as President and Chief Operating OfficerKiniksa Pharmaceuticals, Ltd. announced that on October 17, 2026, the Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals International, plc appointed Ross Moat as President and Chief Operating Officer, effective immediately. Mr. Moat will continue to repo
- Zacks · Sep 17, 12:13 PM EDTKiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's WhyKNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
- MarketBeat · Aug 14, 9:01 PM EDTKiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyKiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-38
- Zacks · Aug 3, 10:00 AM EDTKNSA Q2 Earnings Call Backs Higher ARCALYST Sales OutlookKNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Kiniksa Pharmaceuticals International, plc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.